Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McFarland, Nikolaus
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy	Recruiting	2	80	US	ONO-2808, Placebo	Ono Pharmaceutical Co. Ltd	Multiple System Atrophy (MSA)	08/25	08/25
CT-AMT-130-01, NCT04120493: Safety and Proof-of-Concept (POC) Study with AMT-130 in Adults with Early Manifest Huntington's Disease Jan 2021 - Dec 2021 : Early efficacy data on initial patients for Huntington's disease First biomarker data from trial for Huntington’s disease Nov 2021 - Nov 2021: First biomarker data from trial for Huntington’s disease Safety data from P1/2 trial for Huntington’s disease Feb 2021 - Feb 2021: Safety data from P1/2 trial for Huntington’s disease	Recruiting	1/2	37	US	intra-striatal rAAV5-miHTT, AMT-130, Imitation (sham) surgery	UniQure Biopharma B.V.	Huntington's Disease	04/29	06/29
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort	Recruiting	N/A	4500	Europe, Canada, US, RoW		Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders	Parkinson Disease	12/33	12/33
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	N/A	35000	Europe, Canada, US, RoW		CHDI Foundation, Inc.	Huntington's Disease	01/62	01/62